Medy-Tox CEO Hyeonho Jeong Increases Stake to 18.25% via Open Market Purchases, Signaling Confidence

Hyeonho Jeong, CEO and major shareholder of Medy-Tox, purchased 1,315 common shares through open market transactions on June 25 and 26, 2026.
The purchase prices were 75,924 KRW and 77,000 KRW respectively, increasing Jeong's ownership of specific securities from 17.19% to 18.25%, a 1.06 percentage point rise.
Although the purchased shares represent only 0.018% of total outstanding shares of 7,298,497, insider buying by the CEO is generally viewed as a positive signal of management confidence and commitment to shareholder value.
[AI Summary]The CEO's small open market purchase marginally increased his stake but has limited direct price impact due to its tiny proportion. Nevertheless, it may bolster market confidence and provide downside support, while further treasury stock or dividend actions could follow.